No approval for Sputnik V vaccine yet; Drug authority seeks additional data from Dr Reddy’s

An expert panel of India’s central drug authority has sought additional data and information from Dr Reddy’s Laboratories, which has sought emergency use authorisation for Russian Covid-19 vaccine Sputnik V, while deferring its decision on it till the next meeting, sources said.

In light of a February 24 meeting of the Subject Expert Committee (SEC) on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO), the firm presented the interim safety and immunogenicity data of the Gam-Covid-Vac combined vector vaccine generated in the country, along with the interim data from the ongoing Russian study.

According to the sources, the SEC, which deliberated on the EUA application on Thursday, recommended that the firm should present data pertaining to all immunogenicity parameters, unblinded data of serious adverse events and RT-PCR positive cases, along with causality analysis reported till date for further examination.

“It has also asked the Hyderabad-based firm to submit a comparative analysis of the phase 3 immunogenicity data generated on the Indian and Russian studies at various time points. It has also asked the drug-maker to submit the factsheet,” a source said.

“We have had our meeting with the SEC today and will await the feedback from the CDSCO. We will provide an update once we have the feedback,” Dr Reddy’s Laboratories said in a statement.

On February 19, the firm said it had approached drugs regulator DCGI for emergency use authorisation (EUA) for Sputnik V.

In September last year, Dr Reddy’s partnered with the Russian Direct Investment Fund (RDIF) to conduct the clinical trials of Sputnik V and for its distribution rights in India.

The Drugs Controller General of India (DCGI) has already given the EUA nod to two COVID-19 vaccines — Covaxin of Bharat Biotech and Covishield of Oxford-AstraZeneca, being manufactured by the Serum Institute of India in Pune.

Sputnik V has demonstrated an efficacy rate of 91.6 per cent in the interim analysis of phase 3 clinical trial, which included data on 19,866 volunteers in Russia.

  • Related Posts

    After two years, pharma volumes pick up pace

    NEW DELHI: The domestic pharmaceutical retail market is showing its strongest signs yet of a shift from price-led to demand-led growth. Volume growth crossed 3% in June, the first time…

    NPPA fixes prices of 39 drugs, raises anti-rabies immunoglobulin rate

    The National Pharmaceutical Pricing Authority (NPPA) has allowed an increase in the retail price of anti-rabies immunoglobulin while fixing the retail prices of 39 drug formulations.  According to a gazette…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Employees are Apples of ENTOD’s Eyes, few fall Far from Tree

    Employees are Apples of ENTOD’s Eyes, few fall Far from Tree

    After two years, pharma volumes pick up pace

    After two years, pharma volumes pick up pace

    NPPA fixes prices of 39 drugs, raises anti-rabies immunoglobulin rate

    NPPA fixes prices of 39 drugs, raises anti-rabies immunoglobulin rate

    Tambaram police arrest two persons after seizing 1,100 banned tablets, 5 kg ganja

    Tambaram police arrest two persons after seizing 1,100 banned tablets, 5 kg ganja

    Rajasthan Healthcare Crisis: 8 Mothers Die Post-C-Section

    Rajasthan Healthcare Crisis: 8 Mothers Die Post-C-Section

    Steroid cream misuse fuels spurt in fungal infections

    Steroid cream misuse fuels spurt in fungal infections